New combo therapy aims to shrink kidney tumors before surgery
NCT ID NCT07172386
First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This phase 2 trial tests a three-part approach for advanced kidney cancer: first, a procedure to block blood flow to the tumor, then two drugs (toripalimab and axitinib) before surgery, followed by more toripalimab after surgery. The goal is to see if this makes surgery more successful and controls the cancer longer. The study involves 40 participants and is currently recruiting.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
toripalimab and axitinib
What this could lead to
If successful, this combination could improve surgical outcomes and control advanced kidney cancer more effectively, potentially extending survival.
What could go wrong
This is a small, early-phase trial with only 40 participants. The treatment may cause side effects, and results may not apply to all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RENAL CELL CARCINOMA (RCC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Tianjin Medical University Second Hospital
RECRUITINGTianjin, Tianjin Municipality, 300211, China
Contact Phone: •••-•••-•••• Email: •••••@•••••